Consolidated Financial Results for the Six Months Ended September 30, 2026 (Under Japanese GAAP)

November 12, 2026

Company name	REPROCELL Inc.			Stock exchange listings: Tokyo Growth
Securities code	4978	URL https://www.reprocell.com		
Representative	(Title)	Representative Director and President	(Name)Chikafumi Yokoyama	
Inquiries	(Title)	GM of Management Administration Department	(Name)Koji Yamane	Tel 045-475-3887
Semi-annual statement filing date (as planned)	November 12, 2026		Dividend payable date (as planned)	—

Supplemental material of results：None

Convening briefing of results ： Yes (For Institutional Investors and Analysts)

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the six months ended September 30, 2026 (from April 1, 2026 to September 30, 2026)

(1) Consolidated operating results (cumulative) (Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
Six months ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
September 30, 2026	1,156	18.7	(497)	—	(318)	—	(319)	—
September 30, 2025	974	(26.2)	(546)	—	(483)	—	(486)	—

Note:Comprehensive income For the six months ended September 30, 2026 319 Millions of yen (—%) For the six months ended September 30, 2025 (309) Millions of yen (—%)

	Basic earnings per share	Diluted earnings per share
Six months ended	Yen	Yen
September 30, 2026	(3.24)	—
September 30, 2025	(5.14)	—

(2) Consolidated financial position

	Total assets	Net assets	Capital adequacy ratio	Net assets per share
As of	Millions of yen	Millions of yen	%	Yen
September 30, 2026	11,338	10,288	90.6	98.99
March 31, 2026	9,652	8,846	91.7	93.09

Reference:Owner's equity As of September 30, 2026 10,277 Millions of yen As of March 31, 2026 8,846 Millions of yen

2. Cash dividends

	Dividend per share				
	First quarter	Second quarter	Third quarter	Year end	Annual
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2026	—	0.00	—	0.00	0.00
Fiscal year ending March 31, 2027	—	0.00			
Fiscal year ending March 31, 2027 (Forecast)			—	0.00	0.00

Note:Revisions to the forecast of cash dividends most recently announced：None

3. Consolidated financial forecast for the fiscal year ending March 31, 2027 (from April 1, 2026 to March 31, 2027)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
Fiscal year ending	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
March 31, 2027	2,629	17.7	(630)	-	(458)	-	(458)	-	(4.47)

Note:Revisions to the earnings forecasts most recently announced：None

The Company conducted capital increases through third-party allotments of 2,932,000 common shares each on June 11, 2026, July 16, 2026, September 3, 2026 and October 20, 2026. Basic earnings per share in the Consolidated financial forecast for the fiscal year ending March 31, 2027 is calculated based on the forecast weighted-average number of shares outstanding of 102,469 thousand shares (excluding treasury shares), reflecting the increases in the number of shares from the respective payment dates of these capital increases. No increase in the number of shares resulting from future exercises of share acquisition rights or other transactions has been assumed.

* Notes

(1) Significant changes in the scope of consolidation during the period：None

(2) Adoption of accounting treatment specific to the preparation of semi-annual consolidated financial statements：None

(3) Changes in accounting policies, changes in accounting estimates, and restatement

(i) Changes in accounting policies due to revisions to accounting standards and other regulations ：None

(ii) Changes in accounting policies due to other reasons ：None

(iii) Changes in accounting estimates ：None

(iv) Restatement ：None

(4) Number of issued shares (common shares)

① Number of issued and outstanding shares at the period end (including treasury stock)	As of September 30, 2026	103,943,891 shares	As of March 31, 2026	95,147,891 shares
② Number of treasury stock at the period end	As of September 30, 2026	117,285 shares	As of March 31, 2026	117,256 shares
③ Average number of shares	Six months ended September 30, 2026	98,507,375 shares	Six months ended September 30, 2025	94,685,635 shares

* Semi-annual financial results reports are exempt from review conducted by certified public accountants or an audit firm.

* Proper use of earnings forecasts, and other special matters

(Notes on Forward-Looking Statements)

The forward-looking statements, including earnings forecasts, contained in this document are based on information currently available to the Company and on certain assumptions deemed reasonable by the Company. Actual results and other outcomes may differ significantly due to various factors. For the assumptions underlying the earnings forecasts and other notes concerning the use of the earnings forecasts, please refer to page 8 of the attached materials, "Explanation of Consolidated Financial Forecasts and Other Forward-Looking Information."

(How to Obtain Materials from the Financial Results Briefing)

The Company plans to hold a financial results briefing for institutional investors and analysts on Thursday, December 10, 2026. Materials distributed at the briefing are scheduled to be posted on the Company's website promptly after the briefing.

○Table of Contents of Attached Materials

１．Qualitative Information on Financial Results for the Interim Period 2
（１）Explanation of Operating Results …… 2
（２）Explanation of Financial Position …… 7
（３）Explanation of Consolidated Financial Forecasts and Other Forward-Looking Information 8
２．Semi-annual Consolidated Financial Statements and Major Notes … 9
（１）Semi-annual Consolidated Balance Sheets …… 9
（２）Semi-annual Consolidated Statements of Income and Comprehensive Income 11
Semi-annual Consolidated Statements of Income …… 11
Semi-annual Consolidated Statements of Comprehensive Income …… 12
（３）Semi-annual Consolidated Statements of Cash Flows …… 13
（４）Notes to Semi-annual Consolidated Financial Statements …… 14
（Notes on Going Concern Assumption） …… 14
（Notes in the Event of Significant Changes in Shareholders' Equity） 14
（Changes in the Scope of Consolidation or Scope of Application of the Equity Method） 14
（Changes in Accounting Policies） …… 14
（Changes in Presentation Method） …… 14
（Notes on Segment Information, etc.） …… 15
（Significant Subsequent Events） …… 17
３．Other …… 18
Material Events or Conditions Related to the Going Concern Assumption 18

1. Qualitative Information on Financial Results for the Six Months Ended September 30, 2026

Forward-looking statements herein are based on judgments made as of the end of the semi-annual consolidated accounting period under review.

（1）Explanation of Operating Results

The iPS cell technology that serves as the core technology of the Group has seen increasingly active research worldwide since Professor Shinya Yamanaka established human iPS cells. In recent years, research and development toward practical application has accelerated, including applications in disease elucidation and regenerative medicine. In March 2026, marketing approval was granted for the first time, on a conditional and time-limited basis, for two regenerative medical products using iPS cells for severe heart failure and Parkinson's disease, making the practical application of therapeutic products using iPS cells originating in Japan a reality. In addition, clinical trials are also being conducted for indications such as age-related macular degeneration, spinal cord injury, and head and neck cancer. Progress has also been reported in disease elucidation using patient-derived iPS cells from patients with rare intractable diseases and in clinical trials of new drug candidates.

Against this backdrop, the Group promotes businesses that utilize iPS cell technology by classifying them into two segments: the Research Support Business and the Medical Business. The Research Support Business focuses primarily on applying iPS cells to disease elucidation and drug discovery research, thereby building a short- to medium-term earnings base. Meanwhile, the Medical Business engages in the research and development of regenerative medical products centered on four items - Stemchymal, iPS cell-derived neural glial cell products, TIL therapy, and GPC-1 CAR-T therapy - as well as contract manufacturing of regenerative medical products and clinical laboratory testing services, and is positioned as a pillar of medium- to long-term growth.

The Research Support Business serves customers such as universities, public research institutions, and pharmaceutical companies, providing research reagents, cells, contract iPS cell generation services, cell measurement instruments, and other products and services. Because these products and services are for research use, they do not require marketing approval as pharmaceuticals do, and their distinguishing feature is the ability to commercialize and monetize new technologies in a relatively short period of time. The Group possesses a broad "Human Cell Business Platform" centered on iPS cell technology, and aims to secure stable earnings by globally deploying products and services with strong competitive advantages.

The regenerative medical products being developed in the Medical Business require clinical trials and marketing approval before market launch, and therefore require more time for commercialization than the Research Support Business. However, legal revisions in Japan in 2014 established an environment suitable for the industrialization of regenerative medicine. In particular, the system under the Pharmaceuticals and Medical Devices Act that grants conditional and time-limited approval to regenerative medical products for which safety has been confirmed and efficacy is presumed supports early practical application. Related guidance published by the Ministry of Health, Labour and Welfare in March 2024 clarified the operational standards for this approval system, and is expected to enable the earlier provision of new treatment opportunities to patients. According to a report by the Ministry of Economy, Trade and Industry, the global market size of the regenerative medicine industry is projected to reach approximately ¥17 trillion in 2030, making this a field in which extremely significant growth is expected. In this growth market, the Group will focus management resources on the development of innovative regenerative medical product pipelines and aim to maximize corporate value by addressing unmet medical needs.

By advancing both the Research Support Business, which serves as a short- to medium-term earnings base, and the Medical Business, which serves as a medium- to long-term growth driver, the Group will work to achieve sustainable growth.

As a result, for the six months under review, net sales were ¥1,156 million, up 18.7% year on year; operating loss was ¥497 million, compared with an operating loss of ¥546 million in the same period of the previous fiscal year; ordinary loss was ¥318 million, compared with an ordinary loss of ¥483 million in the same period of the previous fiscal year; and loss attributable to owners of parent was ¥319 million, compared with a loss of ¥486 million in the same period of the previous fiscal year.

Operating results by segment were as follows.

a. Research Support Business

In the Research Support Business, the Group provides research products such as research reagents and cells, as well as contract services such as iPS cell generation and genome editing, to customers including universities, public research institutions, and research laboratories of pharmaceutical companies. Through products and services that incorporate cutting-edge technologies,

the Group supports the development of groundbreaking new drugs and therapies.

In recent years, the pharmaceutical industry has been accelerating a shift "from animal experiments to human cell experiments" due to issues such as animal welfare and differences in results arising from species differences between humans and animals. This trend is expected to significantly shorten the new drug development process and enable the development of new drugs with greater efficacy. Human iPS cells, in particular, are attracting attention as a central element of this shift. For example, the use of iPS cells derived from patients with Alzheimer's disease is expected to accelerate disease elucidation and new drug development.

The Group possesses world-leading technology platforms for human iPS cells, including RNA reprogramming technology, genome editing technology, and technologies for inducing differentiation into various types of cells. The Group has also built an extensive network that enables the procurement of cancer cells and human tissue from medical institutions. Through its "Human Cell Business Platform," which integrates these capabilities, the Group is developing businesses that anticipate the transition "from animal experiments to human cell experiments." Specifically, the Group provides research reagent products, services for generating disease model cells using iPS cells, the banking and provision of human biological samples, and services for pharmacological efficacy testing of new drugs using human tissue. Leveraging these technological capabilities, in April 2025 the Group developed and began selling the "StemEdit™ Human iPSC non-HLA" series of HLA knockout iPS cell lines, which significantly reduce the risk of immune rejection in regenerative medicine. This product will accelerate research and development of "universal donor cells" that address immune rejection, a major challenge in cell transplantation therapy using allogeneic iPS cells.

In addition to its internally developed products, the Group is actively engaged in the introduction and distributor sales of products from other companies. The Group handles a diverse range of research instruments, including electrophysiological cell measurement instruments manufactured by Nanion Technologies of Germany, microbiological testing instruments manufactured by INTERSCIENCE of France, and live imaging systems manufactured by InnoME of Germany. By combining these instruments with the Group's cells and reagents, the Group provides comprehensive solutions to customers.

The Group will continue to actively expand the portfolio of the Research Support Business and strengthen its stable earnings base by supporting the increased efficiency of new drug development and the advancement of innovative therapies.

As a result, net sales were ¥947 million, up 6.7% year on year, and segment profit was ¥70 million, compared with a segment loss of ¥22 million in the same period of the previous fiscal year.

b. Medical Business

In the field of regenerative medicine, research aimed at clinical applications of human somatic stem cells and human iPS cells is being actively pursued worldwide, and regenerative medical products are expected to grow into a huge global industry in the future.

In particular, iPS cells, which possess unlimited proliferative capacity and pluripotency, have the potential to become groundbreaking therapies for intractable diseases for which no effective treatments exist, and there are high expectations for their clinical application. A key issue in the clinical application of iPS cells is ensuring safety. The Group has developed and possesses RNA reprogramming technology for generating high-quality iPS cells optimally suited for clinical application. Leveraging this technological advantage, the Group is vigorously promoting the following businesses in order to achieve early clinical application of iPS cells and related technologies.

The Medical Business promotes the following businesses.



Reference Information

*1: Amyotrophic lateral sclerosis (ALS)

Amyotrophic lateral sclerosis (ALS) is a disease in which the nervous system responsible for bodily movement (motor neurons) degenerates, causing symptoms such as motor impairment due to muscle weakness and dysphagia. Although the disease progresses extremely rapidly, no curative treatment has been established, although drug therapies and other treatments to slow its progression are available. In Japan, ALS is designated as an intractable disease, and the number of patients nationwide is estimated at approximately 10,000.

(a) Somatic Stem Cell Product Stemchymal

Stemchymal is an adipose-derived mesenchymal stem cell product developed by Steminent Biotherapeutics Inc. of Taiwan ("Steminent"). The Company has entered into an exclusive commercial license agreement for spinocerebellar ataxia in Japan, and related patents have also been granted in Japan.

Spinocerebellar ataxia is a rare disease of unknown cause that results in ataxia, including gait disturbance and dysphagia, due to degeneration of nerve cells in the cerebellum, brainstem, and spinal cord. Stemchymal is expected to inhibit the progression of symptoms, and because it is administered by intravenous infusion, it is a less invasive treatment option for patients.

In the Phase II clinical trial conducted in Japan, in which administration began in February 2020 and was completed in May 2022, no serious adverse events were observed in any subject, and safety was confirmed. With respect to efficacy, in the SARA score*, the primary endpoint, a trend was observed in which the increase in scores in the active drug group was suppressed compared with natural history. Furthermore, in a subgroup with a baseline (pre-administration) score of 11 or higher, the active drug group showed a statistically significant improvement compared with the placebo group in the change in score from baseline to Week 52 (P-value = 0.042).

In addition, the Phase II clinical trial conducted by Steminent in Taiwan showed no safety concerns and confirmed improvements in SARA scores and an effect of suppressing disease progression, thereby supporting the results of the Japanese trial. Furthermore, in a clinical trial conducted in the United States involving one patient, long-term improvement in the SARA score over approximately one and a half years was also observed. In November 2024, Steminent was accredited by the Minister of Health, Labour and Welfare as a foreign manufacturer of regenerative medical products, satisfying one of the requirements for the Company to obtain marketing approval in Japan. In March 2026, Steminent also announced the commencement of a Phase II clinical trial of the product in the United States and is pursuing global expansion.

This product was designated as an orphan regenerative medical product in December 2018, making it eligible for support measures such as development cost subsidies of up to 50%, preferential tax treatment, and priority review. Leveraging these results and the benefits of the designation, on June 24, 2026, the Group submitted an application for marketing approval in Japan for the indication of suppressing the progression of ataxia in spinocerebellar ataxia (SCA type 3 and SCA type 6). The product is eligible for priority review, which is expected to be completed within a target period of nine months from acceptance of the application.

In addition, on September 18, 2026, the Company obtained a regenerative medical product marketing license from Kanagawa Prefecture, marking further progress in establishing the framework for the Company to assume responsibility for domestic supply as the marketing authorization holder following approval. Steminent is expected to manufacture the product, while the Company, as the marketing authorization holder, will be responsible for product quality management and post-marketing safety management, and is proceeding with preparations to ensure a smooth commencement of supply after approval. Furthermore, on

September 17, 2026, the Company entered into a basic agreement with TOHO HOLDINGS CO., LTD. toward a partnership concerning domestic distribution and related activities for the product. To facilitate smooth market introduction and stable supply following approval, the parties are discussing and considering arrangements for supplying medical institutions throughout Japan and a distribution system suited to the characteristics of regenerative medical products. The Group will make every effort toward obtaining approval and launching the product so that it can deliver a new treatment option as soon as possible.

* SARA score: An index widely used to evaluate symptoms of spinocerebellar ataxia. It comprehensively quantifies gait, stance, speech, finger movements, and other functions on a scale of 0 to 40 points. The score increases as symptoms worsen.

(b) iPS Cell-Derived Neural Glial Cell Products

The Group generates neural glial cells from iPS cells and conducts research and development of these cells as iPS cell-based regenerative medical products for various neurodegenerative diseases. The Group is currently preparing for the early commencement of a clinical trial for ALS.

In experiments using ALS model rats, meaning rats that reproduce the pathological condition of ALS, the Group obtained results showing that the decline in motor function was significantly suppressed in the group administered iPS cell-derived neural glial cells compared with the non-administered group. It has also been confirmed that the administered iPS cell-derived neural glial cells engrafted in the rats for a long period and activated motor neurons.

Based on these promising non-clinical data, the Group is proceeding with preparations for the early commencement of a clinical trial for ALS.

(c) Tumor-Infiltrating Lymphocyte Infusion Therapy (TIL Therapy)

TIL therapy is a type of adoptive immunotherapy in which tumor-infiltrating lymphocytes, or TILs, are collected from a patient's own cancer tissue, expanded ex vivo on a large scale, and then re-administered to the patient. Since the 1980s, TIL therapy has been used primarily in the United States for advanced malignant melanoma, and high therapeutic efficacy has been reported. The response rate is said to be approximately 70%, and the complete response rate approximately 20%; it is known that many complete responders do not experience recurrence. In February 2024, TIL therapy for metastatic melanoma was approved by the U.S. FDA as the first cellular immunotherapy for a solid tumor, with a drug price of US$515,000.

In June 2023, the Company entered into a joint research agreement with the Department of Obstetrics and Gynecology, Keio University School of Medicine, concerning technology transfer of the TIL manufacturing method for "Advanced Medical Care B: Phase II Clinical Trial of Short-Term Cultured Anti-Tumor Lymphocyte Infusion Therapy Using Non-Myeloablative Preconditioning and Low-Dose IL-2 for Advanced Cervical Cancer," and completed the technology transfer. Because TIL therapy requires advanced culture technology, the number of facilities capable of implementing it is limited worldwide.

In November 2024, this Advanced Medical Care program was resumed at Keio University, and the second patient was administered TILs manufactured by the Company. Clinical research under this Advanced Medical Care program has continued thereafter.

In parallel with the contract manufacturing of TILs for this clinical trial, the Group positions TIL therapy as one of the pillars of its regenerative medical product pipeline. In October 2024, the Company entered into a new joint research agreement with the Department of Obstetrics and Gynecology, Keio University School of Medicine, concerning a novel TIL culture method. Furthermore, in July 2026, "Development of Manufacturing Process for Tumor-Infiltrating Lymphocyte (TIL) Regenerative Medical Products for Advanced/Recurrent Cervical Cancer" was selected under the "Project for the Development of Fundamental Technologies for the Industrialization of Regenerative Medicine and Gene Therapy," a publicly solicited program of the Japan Agency for Medical Research and Development (AMED).

(d) Glypican-1 Chimeric Antigen Receptor T-cell Therapy (GPC-1 CAR-T Therapy)

Chimeric antigen receptor T cell therapy, or CAR-T therapy, is an immune cell therapy in which a patient's own T cells, which are immune cells, are genetically modified to recognize and attack specific cancer antigens, and are then returned to the patient. CAR-T therapy has already been put into practical use for hematologic cancers, and research and development for its application to solid tumors is being vigorously pursued worldwide.

In this business, the Group conducts research and development of GPC-1 CAR-T cell therapy, which targets the cancer antigen glypican-1, or GPC-1. GPC-1 is rarely expressed in normal adult tissues, while it is specifically and highly expressed in a wide range of solid tumors, including esophageal cancer, cervical cancer, lung squamous cell carcinoma, and pancreatic cancer. Accordingly, CAR-T therapy targeting GPC-1 is expected to be a promising treatment for these intractable solid tumors.

In December 2024, this research and development project was selected for the "Project for the Development of Fundamental Technologies for the Industrialization of Regenerative Medicine and Gene Therapy," a publicly solicited program of the Japan Agency for Medical Research and Development (AMED). The Group has entered into commissioned research agreements with

the Department of Early Medical Development, Graduate School of Medicine, Kyoto University, and the Department of Immunology, School of Medicine, International University of Health and Welfare, and is conducting joint research.
The Group is currently preparing for the early commencement of a clinical trial for esophageal cancer.

(e) Contract Manufacturing Business for iPS Cell-Based Regenerative Medical Products
Research and development of regenerative medicine using iPS cells is being actively pursued worldwide for indications such as age-related macular degeneration, Parkinson's disease, ischemic cardiomyopathy, and spinal cord injury. iPS cells used in regenerative medicine must meet extremely high safety and quality standards, and compliance with the stringent regulatory guidelines of each country is essential.
The Group has developed and possesses cutting-edge RNA reprogramming technology that minimizes the risk of genetic mutations and the residual risk of exogenous genes and viruses, enabling the safe and high-quality generation of iPS cells optimally suited for clinical application. The Group's products and services in this business are broadly classified into "clinical-grade iPS cells" primarily for pharmaceutical companies and other corporate customers, and "Personal iPS" for individuals.
For "clinical-grade iPS cells," the Group provides iPS cells manufactured under a GMP (Good Manufacturing Practice) compliant manufacturing system as starting materials for regenerative medical products. A strength of the Company's iPS cells is that they comply with pharmaceutical regulatory requirements in Japan, the United States, and Europe, and can therefore be widely used globally. In addition, the Company's clinical-grade iPS cells have been registered in a Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA), which can simplify procedures when customer companies file approval applications in the United States. Their high safety and quality have been demonstrated, among other things, through the fact that in February 2025, Gameto Inc. of the United States, to which the Company supplies cells, obtained IND clearance from the FDA for a Phase III clinical trial using technology based on those iPS cells.
During the fiscal year under review, based on the robust foundation described above, the Group further advanced global expansion and the establishment of integrated contract services.
With respect to its site structure, in addition to the existing cell processing facility "Tonomachi REPROCELL Regenerative Medicine Center" located in the Kanagawa Life Innovation Center, a licensed facility for the manufacture of specified processed cells (Facility No. FA3200006), and the GMP facilities of REPROCELL USA Inc. in the United States, Histocell of Spain, a partner company in which the Company has invested, obtained GMP certification from the Spanish Agency of Medicines and Medical Devices (AEMPS) in October 2025 for the manufacture of master cell banks (MCBs) and working cell banks (WCBs) using the Company's clinical-grade iPS cells. This established a framework for globally expanding the contract manufacturing business through a three-site structure in Japan, the United States, and Europe.
On the technology side, in January 2026 the Company began providing "StemEdit™," a clinical-grade gene editing service based on the AI-designed genome editing system "OpenCRISPR-1™." This technology is an artificial design system based on a large language model (LLM), and has high editing efficiency and the ability to reduce off-target effects. This enables the efficient generation of universal donor iPS cells with a reduced risk of immune rejection. In addition, as an alternative to conventional gene editing technologies that involve complex licensing issues, it has groundbreaking features that resolve intellectual property and commercial challenges and reduce barriers to commercialization in the development of cell therapy products.
Subsequently, in March 2026, the Company began MCB manufacturing services for clinical-grade iPS cells at the GMP manufacturing facility of REPROCELL USA Inc. in the United States. As a result, the Group has established a framework that can provide a series of workflows in an integrated manner, from "donor selection," "seed clone manufacturing," and "clinical-grade gene editing using StemEdit™" through to "GMP cell banking." By using the Company's services, customer companies can reduce uncertainties related to regulatory requirements and manufacturing processes in each country, and can build more rational and feasible development roadmaps.
"Personal iPS" is a service that generates and stores an individual's iPS cells in preparation for future illness. By preparing individual-specific iPS cells in advance, the service is expected to shorten treatment time when needed and minimize the risk of immune rejection. The Company is continuing to develop sales to domestic customers and foreign visitors to Japan through collaboration with JTB Corp. ("JTB").
iPS cell-derived exosomes are granular substances with diameters of 50 to 150 nm that play a role in intercellular communication, and are attracting attention as next-generation medical tools. The Group manufactures exosomes derived from iPS cells generated using a virus-free mRNA method, thereby eliminating the risk of contamination by exogenous viruses, at GMP-compliant facilities. The Company has entered into a general distributor agreement with JTB for this product, and is seeking to expand sales by leveraging JTB's global network.

(f) Contract Clinical Laboratory Testing Services
Since registering as a clinical laboratory in 2005, the Group has conducted clinical tests related to organ transplantation, including HLA typing and anti-HLA antibody testing, and has a track record of transactions with more than 300 medical

institutions nationwide.
In April 2023, the Group launched "Well-Mill," a mail-in testing service that enables users to conveniently check their health status at home. Using saliva as the specimen, the service measures hormones related to "stress," "menopause," "male hormones," and "female hormones," and can be used for day-to-day health management. In addition, in January 2026 the Group began providing a "Gene Age Measurement Kit" that measures an individual's biological age, or gene age, by analyzing how genes function in cells contained in saliva, based on the latest epigenetics research. This service contributes to people's health management and improved quality of life (QOL) by enabling them to objectively understand their own biological age and use that information to improve lifestyle habits.
The Group also provides a "Neoantigen Detection Service" as a new service related to personalized cancer medicine. This service analyzes genetic information from each patient's cancer tissue and identifies neoantigens, which are unique markers.
For pharmaceutical companies, the Group provides contract testing services in clinical trials. The Group has research facilities in four locations - Japan, the United States, the United Kingdom, and India - and has established a system capable of supporting global-scale clinical trials. Through this system, the Group provides high-quality testing services that support pharmaceutical companies' new drug development and has earned international trust.
The Group is also advancing initiatives in personalized medicine. REPROCELL Europe Ltd. of the Group, together with IBM Research and the United Kingdom's STFC Hartree Centre, successfully developed "Pharmacology-AI," a machine learning platform specialized for personalized medicine. This platform enables big data analysis in pharmaceutical development and data analysis required for personalized medicine. Going forward, the Group will create new businesses using Pharmacology-AI and strengthen its promotion of personalized medicine and support for pharmaceutical companies. As a specific initiative, the Group established "ReproRegistry," a United Kingdom-based medical volunteer registration system. This system works in conjunction with Pharmacology-AI to identify subjects best suited for clinical trials with a high degree of precision, and the Group will develop it into a core foundation for next-generation clinical trial support services.

In September 2026, the Group newly positioned the "Well-Aging Business" as a business that brings the scientific knowledge it has developed primarily in research and medical fields to products and services that support the daily health management of a wider range of people, and began sales of "Gurutama Aging," a well-aging supplement, as its first product. Going forward, in addition to testing services that help individuals "understand" their physical condition, such as the "Gene Age Measurement Kit," the Group will expand its offerings to include products and services that support daily health management appropriate to age, and will further develop the Well-Aging Business.

As a result, net sales were ¥209 million, up 141.6% year on year, and segment loss was ¥23 million, compared with a segment loss of ¥119 million in the same period of the previous fiscal year.

In addition, corporate expenses not allocated to individual business segments, such as expenses related to administrative departments, amounted to ¥365 million, compared with ¥341 million in the same period of the previous fiscal year.

(2) Explanation of Financial Position

1) Assets, Liabilities and Net Assets

(Assets)

Current assets at the end of the semi-annual consolidated accounting period decreased by ¥601 million compared with the end of the previous fiscal year, to ¥6,727 million. This was mainly due to an increase of ¥212 million in cash and deposits, partially offset by a decrease of ¥868 million in securities. Non-current assets increased by ¥2,287 million compared with the end of the previous fiscal year, to ¥4,610 million. This was mainly due to an increase of ¥2,337 million in investment securities.

(Liabilities)

Current liabilities at the end of the semi-annual consolidated accounting period decreased by ¥56 million compared with the end of the previous fiscal year, to ¥560 million. This was mainly due to a decrease of ¥47 million in advances received. Non-current liabilities increased by ¥300 million compared with the end of the previous fiscal year, to ¥488 million. This was mainly due to an increase of ¥300 million in deferred tax liabilities.

(Net Assets)

Net assets at the end of the semi-annual consolidated accounting period increased by ¥1,442 million compared with the end of the previous fiscal year, to ¥10,288 million. This was mainly due to increases of ¥555 million in share capital, ¥326 million in retained earnings and ¥649 million in valuation difference on available-for-sale securities, partially offset by a decrease of ¥90

million in capital surplus.

2) Cash Flows

Cash and cash equivalents (hereinafter referred to as "funds") at the end of the semi-annual consolidated accounting period increased by ¥212 million compared with the end of the previous fiscal year, to ¥2,815 million.

The cash flows for the semi-annual consolidated accounting period and the principal factors affecting them were as follows.

(Cash Flows from Operating Activities)

Net cash used in operating activities during the semi-annual consolidated accounting period was ¥343 million, compared with net cash used of ¥342 million in the corresponding period of the previous fiscal year. This was mainly attributable to cash outflows of ¥43 million arising from an increase in trade receivables, ¥17 million arising from an increase in inventories, ¥10 million arising from a decrease in trade payables and ¥318 million corresponding to loss before income taxes, partially offset by receipts of ¥61 million in interest and dividends and ¥61 million in subsidies.

(Cash Flows from Investing Activities)

Net cash used in investing activities during the semi-annual consolidated accounting period was ¥531 million, compared with net cash provided of ¥122 million in the corresponding period of the previous fiscal year. This was mainly due to proceeds of ¥2,100 million from the sale and redemption of short-term and long-term investment securities, which were more than offset by payments of ¥2,619 million for the purchase of investment securities.

(Cash Flows from Financing Activities)

Net cash provided by financing activities during the semi-annual consolidated accounting period was ¥1,100 million, compared with no change in funds in the corresponding period of the previous fiscal year. This was mainly due to proceeds of ¥1,100 million from the issuance of shares and share acquisition rights.

(3) Explanation of Consolidated Financial Forecasts and Other Forward-Looking Information

There is no change to the full-year consolidated financial forecast for the fiscal year ending March 31, 2027 announced on May 14, 2026.

2. Semi-annual Consolidated Financial Statements and Major Notes

(1) Semi-annual Consolidated Balance Sheets

(Thousands of yen)

	As of March 31, 2026	As of September 30, 2026
Assets		
Current assets		
Cash and deposits	2,603,703	2,815,779
Accounts receivable - trade	336,054	375,018
Securities	3,904,102	3,035,421
Merchandise and finished goods	127,359	119,864
Work in process	69,659	88,175
Raw materials and supplies	79,848	83,491
Other	213,173	215,249
Allowance for doubtful accounts	(4,539)	(5,318)
Total current assets	7,329,361	6,727,680
Non-current assets		
Property, plant and equipment		
Buildings and structures, net	24,581	23,200
Machinery, equipment and vehicles, net	146,648	128,686
Tools, furniture and fixtures, net	111,179	97,911
Construction in progress	-	2,668
Total property, plant and equipment	282,409	252,467
Intangible assets		
Goodwill	5,426	4,069
Other	8,421	7,234
Total intangible assets	13,847	11,304
Investments and other assets		
Investment securities	1,914,189	4,251,687
Deferred tax assets	59,155	58,219
Other	58,402	41,821
Allowance for doubtful accounts	(5,049)	(4,631)
Total investments and other assets	2,026,697	4,347,096
Total non-current assets	2,322,954	4,610,868
Total assets	9,652,315	11,338,549

(Thousands of yen)

	As of March 31, 2026	As of September 30, 2026
Liabilities		
Current liabilities		
Accounts payable - trade	141,808	129,629
Accounts payable - other	87,367	81,584
Income taxes payable	25,537	25,875
Contract liabilities	40,672	53,919
Advances received	116,629	69,416
Provision for bonuses	8,710	10,628
Other	196,508	189,638
Total current liabilities	617,234	560,691
Non-current liabilities		
Deferred tax liabilities	176,741	477,383
Asset retirement obligations	9,125	9,147
Other	2,487	2,436
Total non-current liabilities	188,354	488,967
Total liabilities	805,589	1,049,659
Net assets		
Shareholders' equity		
Share capital	2,720,149	3,275,763
Capital surplus	6,276,107	6,185,303
Retained earnings	(533,398)	(206,601)
Treasury shares	(916)	(916)
Total shareholders' equity	8,461,940	9,253,548
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	325,433	974,489
Foreign currency translation adjustment	59,352	49,533
Total accumulated other comprehensive income	384,785	1,024,023
Share acquisition rights	-	11,317
Total net assets	8,846,726	10,288,889
Total liabilities and net assets	9,652,315	11,338,549

(2) Semi-annual Consolidated Statements of Income and Comprehensive Income

(Semi-annual Consolidated Statements of Income)

(Thousands of yen)

	Six months ended September 30, 2025	Six months ended September 30, 2026
Net sales		
Net sales of finished goods	549,788	735,299
Service revenue	424,277	420,892
Total net sales	974,065	1,156,192
Cost of sales		
Cost of finished goods sold	363,229	375,620
Cost of service operations	223,890	212,630
Total cost of sales	587,119	588,251
Gross profit	386,946	567,941
Selling, general and administrative expenses		
Research and development expenses	308,505	394,580
Other Selling, general and administrative expenses	625,071	671,069
Total selling, general and administrative expenses	933,577	1,065,650
Operating loss	(546,630)	(497,709)
Non-operating income		
Interest income	41,493	62,293
Subsidy income	—	105,347
Foreign exchange gains	45,008	31,804
Other	1,185	463
Total non-operating income	87,687	199,908
Non-operating expenses		
Share of loss of entities accounted for using equity method	23,470	—
Share issuance costs	—	19,519
Other	975	1,334
Total non-operating expenses	24,445	20,854
Ordinary loss	(483,389)	(318,654)
Loss before income taxes	(483,389)	(318,654)
Income taxes - current	2,952	965
Total income taxes	2,952	965
Loss	(486,341)	(319,620)
Loss attributable to owners of parent	(486,341)	(319,620)

(Semi-annual Consolidated Statements of Comprehensive Income)

(Thousands of yen)

	Six months ended September 30, 2025	Six months ended September 30, 2026
Loss	(486,341)	(319,620)
Other comprehensive income		
Valuation difference on available-for-sale securities	163,094	649,056
Foreign currency translation adjustment	196	(9,818)
Share of other comprehensive income of entities accounted for using equity method	13,576	-
Total other comprehensive income	176,866	639,238
Comprehensive income	(309,474)	319,617
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	(309,474)	319,617

(3) Semi-annual Consolidated Statements of Cash Flows

(Thousands of yen)

	Six months ended September 30, 2025	Six months ended September 30, 2026
Cash flows from operating activities		
Loss before income taxes	(483,389)	(318,654)
Amortization of goodwill	1,356	1,356
Depreciation	33,016	40,541
Share-based payment expenses	24,858	28,148
Increase (decrease) in allowance for doubtful accounts	(3,791)	550
Increase (decrease) in provision for bonuses	(1,728)	2,219
Interest income	(41,493)	(62,293)
Subsidy income	—	(105,347)
Share issuance costs	—	19,519
Share of loss (profit) of entities accounted for using equity method	23,470	—
Foreign exchange losses (gains)	(28,162)	9,540
Decrease (increase) in trade receivables	134,634	(43,011)
Decrease (increase) in inventories	(32,935)	(17,828)
Increase (decrease) in trade payables	16,143	(10,075)
Increase (decrease) in accounts payable - other	(26,301)	(23,361)
Increase (decrease) in other current liabilities	(16,629)	(2,431)
Other, net	(8,495)	16,408
Subtotal	(409,446)	(464,718)
Interest and dividends received	41,166	61,623
Subsidies received	29,950	61,442
Income taxes paid	(3,913)	(1,927)
Net cash provided by (used in) operating activities	(342,243)	(343,579)
Cash flows from investing activities		
Purchase of short-term and long-term investment securities	—	(2,619,120)
Proceeds from sale and redemption of short-term and long-term investment securities	156,162	2,100,000
Purchase of property, plant and equipment	(33,515)	(12,244)
Net cash provided by (used in) investing activities	122,647	(531,364)
Cash flows from financing activities		
Proceeds from issuance of shares and share acquisition rights	—	1,100,855
Net cash provided by (used in) financing activities	—	1,100,855
Effect of exchange rate change on cash and cash equivalents	31,360	(13,835)
Net increase (decrease) in cash and cash equivalents	(188,235)	212,076
Cash and cash equivalents at beginning of period	2,823,367	2,603,703
Cash and cash equivalents at end of period	2,635,132	2,815,779

(4) Notes to Semi-annual Consolidated Financial Statements

（Notes on Going Concern Assumption）

Not applicable.

（Notes in the Event of Significant Changes in Shareholders' Equity）

The Company received payments from CVI Investments, Inc. for capital increases through third-party allotments on June 11, 2026, July 16, 2026 and September 3, 2026, resulting in increases of ¥555,614 thousand each in share capital and capital surplus during the semi-annual consolidated accounting period. In addition, on July 31, 2026, the Company reduced the amount of legal capital surplus and disposed of surplus to cover accumulated losses, resulting in a decrease of ¥646,418 thousand in capital surplus and an increase of ¥646,418 thousand in retained earnings. As a result, at the end of the semi-annual consolidated accounting period, share capital amounted to ¥3,275,763 thousand, capital surplus to ¥6,185,303 thousand and retained earnings to negative ¥206,601 thousand.

(Changes in the Scope of Consolidation or Scope of Application of the Equity Method)

Not applicable.

（Changes in Accounting Policies）

Not applicable.

(Changes in Presentation Method)

(Semi-annual Consolidated Statements of Cash Flows)

In the previous semi-annual consolidated accounting period, "Proceeds from redemption of securities" and "Proceeds from redemption of investment securities" were presented separately under "Cash flows from investing activities." In the current semi-annual consolidated accounting period, these items are presented as "Proceeds from sale and redemption of short-term and long-term investment securities" in order to present cash flows relating to fund management on an aggregated basis, more clearly reflect the substance of the transactions and achieve consistency with the presentation in the annual consolidated statements of cash flows. To reflect this change in presentation, the semi-annual consolidated statements of cash flows for the previous semi-annual consolidated accounting period have been reclassified.

As a result, the ¥100,000 thousand previously presented as "Proceeds from redemption of securities" and the ¥56,162 thousand previously presented as "Proceeds from redemption of investment securities" in the semi-annual consolidated statements of cash flows for the previous semi-annual consolidated accounting period have been reclassified and presented as ¥156,162 thousand under "Proceeds from sale and redemption of short-term and long-term investment securities."

(Notes on Segment Information, etc.)

【Segment Information】

I. Previous semi-annual consolidated accounting period (from April 1, 2025 to September 30, 2025)

1. Information on Net Sales and Profit or Loss by Reportable Segment and Disaggregation of Revenue

(Thousands of yen)

	Reportable segments			Reconciling items	Per semi-annual consolidated financial statements
	Research Support Business	Medical Business	Reportable segments		
Sales					
Japan	116,546	84,383	200,930	—	200,930
United States	393,958	2,195	396,154	—	396,154
United Kingdom	340,341	—	340,341	—	340,341
India	36,640	—	36,640	—	36,640
Revenue arising from contracts with customers	887,486	86,579	974,065	—	974,065
Revenues from external customers	887,486	86,579	974,065	—	974,065
Net sales	887,486	86,579	974,065	—	974,065
Ordinary profit (loss)	(22,850)	(119,109)	(141,959)	(341,429)	(483,389)

Note: 1. The adjustment to segment loss, negative ¥341,429 thousand, mainly represents corporate expenses such as general and administrative expenses not attributable to reportable segments.

2. Segment loss is reconciled with ordinary loss in the semi-annual consolidated statements of income.

2. Information on Impairment Losses on Non-Current Assets or Goodwill, etc. by Reportable Segment

Not applicable.

II. Current semi-annual consolidated accounting period (from April 1, 2026 to September 30, 2026)

1. Information on Net Sales and Profit or Loss by Reportable Segment and Disaggregation of Revenue

(Thousands of yen)

	Reportable segments			Reconciling items	Per semi-annual consolidated financial statements
	Research Support Business	Medical Business	Reportable segments		
Sales					
Japan	142,311	207,919	350,231	-	350,231
United States	479,188	1,271	480,460	-	480,460
United Kingdom	278,590	-	278,590	-	278,590
India	46,909	-	46,909	-	46,909
Revenue arising from contracts with customers	947,000	209,191	1,156,192	-	1,156,192
Revenues from external customers	947,000	209,191	1,156,192	-	1,156,192
Net sales	947,000	209,191	1,156,192	-	1,156,192
Ordinary profit (loss)	70,493	(23,665)	46,827	(365,482)	(318,654)

Note: 1. The adjustment to segment profit or loss, negative ¥365,482 thousand, mainly represents corporate expenses such as general and administrative expenses not attributable to reportable segments.

2. Segment profit or loss is reconciled with ordinary loss in the semi-annual consolidated statements of income.

2. Information on Impairment Losses on Non-Current Assets or Goodwill, etc. by Reportable Segment

Not applicable.

（Significant Subsequent Events）

On May 27, 2026, the Company entered into an Equity Program Agreement (the "Equity Program Agreement") with CVI Investments, Inc. (the "Allottee"), managed by Heights Capital Management, Inc., a U.S. institutional investor, to establish a share and share acquisition rights issuance program. Based on this issuance program established under the Equity Program Agreement, the Board of Directors resolved on October 5, 2026, as the fourth issuance under the program, to issue new shares and the 20th series of share acquisition rights of REPROCELL Inc. to the Allottee through a third-party allotment. The related payment procedures were completed on October 20, 2026.

Details

1. Overview of the Issuance of the Common Shares

（1）	Payment date	October 20, 2026
（2）	Number of new shares to be issued	2,932,000 common shares
（3）	Issue price	¥119 per share
（4）	Amount of funds to be raised	¥348,908,000
（5）	Method of offering or allotment	Through third-party allotment.
（6）	Amount of Stated Capital to be Increased	¥174,454,000 (¥59.5 per share)
（7）	Amount of Legal Capital Surplus to be Increased	¥174,454,000 (¥59.5 per share)
（8）	Allottee	CVI Investments, Inc.

2. Overview of the Issuance of the Stock Acquisition Rights

（1）	Allotment date	October 20, 2026
（2）	Number of Stock Acquisition Rights Issued	29,320 units
（3）	Issue price	¥117 per share acquisition right (¥3,430,440 in total)
（4）	Number of potential shares resulting from the issuance	Number of potential shares: 2,932,000 shares (100 shares per Stock Acquisition Right) The exercise price of the Stock Acquisition Rights will not be subject to revision and therefore has no upper or lower limit.
（5）	Amount of funds to be raised	¥469,618,440 (Note)
（6）	Exercise price	¥159 per share
（7）	Exercise period	From October 21, 2026 to October 18, 2030
（8）	Method of offering or allotment	Through third-party allotment.
（9）	Allottee	CVI Investments, Inc.

Note: The amount of funds to be raised is the amount calculated assuming that all of the Stock Acquisition Rights are exercised at the initial exercise price. If the exercise price is adjusted, the amount of funds to be raised will increase or decrease. In addition, if the Stock Acquisition Rights are not exercised within the exercise period, or if the Company acquires the Stock Acquisition Rights and cancels them, the amount of funds raised will decrease.

３．Other

Material Events or Conditions Related to the Going Concern Assumption

Due to reasons such as research and development expenses and clinical trial expenses for iPS cells and regenerative medical products being incurred in advance of revenue, the Company continues to record operating losses, and there are events or conditions that may raise significant doubt regarding the going concern assumption.

However, at the end of the semi-annual consolidated accounting period, the Group had a stable financial base, with cash and deposits of ¥2,815 million and securities held for short-term fund management of ¥3,035 million. In order to resolve this situation, the Group is actively promoting sales by utilizing its global sales platform. To improve the efficiency of the Group's management structure, the Group is pursuing sales and marketing activities tailored to regional characteristics and promoting cooperation among Group companies in both sales and technology, while minimizing investment and operating costs, with the aim of achieving profitability at an early stage.